User:Mr. Ibrahem/Osimertinib

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Osimertinib
Clinical data
Trade namesTagrisso, others
Other namesAZD9291, mereletinib, osimertinib mesilate (JAN JP), osimertinib mesylate (USAN US)
AHFS/Drugs.comMonograph
MedlinePlusa616005
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth tablets
Drug classTyrosine kinase inhibitor[1]
Legal status
Legal status
Pharmacokinetic data
Protein bindingProbably high[2]
MetabolismOxidation (CYP3A)
Elimination half-life48 hours
ExcretionFeces (68%), urine (14%)
Identifiers
  • N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
Chemical and physical data
FormulaC28H33N7O2
Molar mass499.619 g·mol−1
3D model (JSmol)
  • CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
  • InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)
  • Key:DUYJMQONPNNFPI-UHFFFAOYSA-N

Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung cancer (NSCLC) with certain mutations in the EGFR gene.[3] It is taken by mouth.[1]

Common side effects include diarrhea, rash, sore mouth, tiredness, and liver inflammation.[1] Other side effects may include pneumonitis, QT prolongation, cardiomyopathy, and eye inflammation.[1] Use in pregnancy may harm the baby.[1] It is a tyrosine kinase inhibitor.[1]

Osimertinib was approved for medical use in the United States in 2015 and in Europe in 2016.[1][3] In the United Kingdom it costs the NHS about £5,800 per month as of 2021.[4] In the United States this amount costs about 16,000 USD.[5]

References[edit]

  1. ^ a b c d e f g h "Osimertinib Monograph for Professionals". Drugs.com. Archived from the original on 21 January 2021. Retrieved 9 November 2021.
  2. ^ a b "Tagrisso- osimertinib tablet, film coated". DailyMed. 5 June 2020. Archived from the original on 29 October 2020. Retrieved 16 October 2020.
  3. ^ a b c d e "Tagrisso EPAR". European Medicines Agency (EMA). Archived from the original on 17 October 2020. Retrieved 16 October 2020.
  4. ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1038. ISBN 978-0857114105.
  5. ^ "Tagrisso Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 5 May 2021. Retrieved 9 November 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Osimertinib&oldid=1169405124"